MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

BACKGROUND: Prostate cancer is a common disease in men and at present there is no effective therapy available due to its recurrence despite androgen deprivation therapy. The epidermal growth factor receptor family (EGFR/HER1, HER2/neu and HER3)/PI3K/Akt signaling axis has been implicated in prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wenqing, Cooke, Larry S, Stejskal, Amy, Riley, Christopher, Croce, Kimiko Della, Saldanha, Jose W, Bearss, David, Mahadevan, Daruka
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685437/
https://www.ncbi.nlm.nih.gov/pubmed/19432987
http://dx.doi.org/10.1186/1471-2407-9-142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685437/
https://www.ncbi.nlm.nih.gov/pubmed/19432987
http://dx.doi.org/10.1186/1471-2407-9-142

Ejemplares similares